BioNTech (NASDAQ:BNTX) PT Raised to $131.00

BioNTech (NASDAQ:BNTX) had its price target increased by UBS Group from $97.00 to $131.00 in a report published on Wednesday morning, Benzinga reports. The brokerage currently has a neutral rating on the stock.

A number of other research analysts have also recently weighed in on the stock. Jefferies Financial Group raised shares of BioNTech from a hold rating to a buy rating and lifted their price target for the company from $96.00 to $150.00 in a research report on Tuesday. Bank of America lifted their price objective on shares of BioNTech from $125.00 to $150.00 and gave the company a buy rating in a research note on Monday, September 16th. Hsbc Global Res raised shares of BioNTech from a hold rating to a strong-buy rating in a report on Friday, August 2nd. TD Cowen cut their price objective on shares of BioNTech from $98.00 to $85.00 and set a hold rating on the stock in a report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. upgraded BioNTech from an underweight rating to a neutral rating and boosted their price target for the stock from $91.00 to $125.00 in a research note on Monday, September 16th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of Moderate Buy and a consensus target price of $124.54.

BioNTech Stock Performance

BioNTech stock opened at $112.28 on Wednesday. The firm has a market capitalization of $26.69 billion, a P/E ratio of 227.96 and a beta of 0.23. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average price of $90.26 and a 200 day moving average price of $90.47.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The company had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. During the same period in the prior year, the firm earned ($0.86) earnings per share. The firm’s quarterly revenue was down 23.3% on a year-over-year basis. Equities research analysts anticipate that BioNTech will post -2.8 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BNTX. Jump Financial LLC bought a new position in shares of BioNTech in the fourth quarter worth $268,000. Quadrant Capital Group LLC bought a new stake in BioNTech during the fourth quarter worth approximately $85,000. Dynamic Technology Lab Private Ltd raised its holdings in BioNTech by 2.5% during the fourth quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company’s stock worth $492,000 after purchasing an additional 116 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of BioNTech by 207.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,583 shares of the company’s stock worth $273,000 after buying an additional 1,743 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in BioNTech by 6.8% during the fourth quarter. Wells Fargo & Company MN now owns 82,171 shares of the company’s stock worth $8,672,000 after acquiring an additional 5,227 shares during the period. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.